Feature | Heart Valve Technology | May 25, 2017

Lotus TAVR System Shows Superior Efficacy to CoreValve in Global REPRISE III Trial

One-year data show Lotus is superior to CoreValve in stroke, death and paravalvular leak
 

The Boston Scientific Lotus TAVR Valve

May 25, 2017 — Positive results from the REPRISE III clinical trial, presented at the annual EuroPCR Scientific Program, in Paris, demonstrated that the Boston Scientific Lotus Valve System, a transcatheter aortic valve implantation (TAVI) system, showed superiority over the Medtronic CoreValve TAVR System platform for the primary effectiveness endpoint and non-inferiority for the primary safety endpoint.

The REPRISE III clinical trial data will be used to support U.S. Food and Drug Administration (FDA) premarket approval for the Lotus Valve.

The primary effectiveness endpoint, a composite of all death, disabling stroke and moderate or greater paravalvular aortic leakage (PVL) at one year, was lower with the Lotus compared to the CoreValve platform (16.7 vs. 29%, p<0.001). The Lotus also demonstrated non-inferiority to CoreValve platform for the primary safety endpoint which was a composite of all-cause mortality, stroke, life-threatening and major bleeding events, stage two or three acute kidney injury or major vascular complications through 30 days.

The pre-specified secondary endpoint demonstrated the Lotus Valve system had significantly lower rates of moderate to severe PVL occurrences when compared to the CoreValve platform (2 vs. 11.1%, p<0.001).

“The excellent results seen in this large randomized trial, particularly the superior performance in efficacy and the continued demonstration of low PVL rates, further establish the advantages of the Lotus Valve system,” said Ted E. Feldman, M.D., director, cardiac catheterization laboratory, NorthShore University HealthSystem in Evanston, Illinois, and co-investigator of the REPRISE III trial. “With the Lotus Valve system, I have confidence that I can position the valve accurately in every case and achieve good outcomes for my patients.”

REPRISE III is the first head-to-head pivotal study comparing two different TAVI platforms: the Lotus Valve system and the CoreValve platform, including both CoreValve and EvolutR. It is a multi-center, randomized controlled trial that included 912 patients from the United States, Europe, Canada and Australia with severe aortic stenosis who were considered to be at high or extreme risk for surgical valve replacement.

“We are very excited by the performance of the Lotus Valve system in this trial as it represents a crucial piece of clinical evidence for the Lotus platform,” said Ian Meredith, M.D., executive vice president and global chief medical officer, Boston Scientific. “We believe that these data, along with upcoming findings to be shared from the RESPOND and RESPOND Extension studies, can further illustrate the unique clinical benefits that this system offers physicians for the treatment of patients.”

 

Related Content on the Lotus TAVR Valve System

REPRISE II Data Show Sustained Performance At One Year For Boston Scientific Lotus Valve System

Boston Scientific Lotus Valve System Demonstrates Extremely Low PVL Rates

Advances and Future Directions for Transcatheter Valves

Boston Scientific Gains European Approval for Next Generation Lotus Edge TAVR System

Boston Scientific Enrolls First Patients in U.S. Trial of Lotus Valve System

 

The Lotus Valve System is not available for sale in the United States.

For more information: www.bostonscientific.com

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
Roxwood Medical Announces Agreement With Abbott for U.S. Product Distribution
News | Catheters| August 09, 2017
Roxwood Medical Inc. recently announced it has entered into an exclusive agreement with Abbott for distribution of...
Overlay Init